Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), sold 88,447 shares at $56.63 ($5.1M) on 2021-05-03, disclosed to the SEC on 2021-05-05.
Open-market sale of $5.1M KROS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.04 | 5,383 | $302K | 6.0% |
| 2 | $56.04 | 3,509 | $197K | 3.9% |
| 3 | $56.04 | 3,509 | $197K | 3.9% |
| 4 | $56.04 | 5,383 | $302K | 6.0% |
| 5 | $56.63 | 6,841 | $387K | 7.6% |
| 6 | $56.63 | 6,841 |
| $387K |
| 7.6% |
| 7 | $56.63 | 4,460 | $253K | 5.0% |
| 8 | $56.63 | 4,460 | $253K | 5.0% |
| 9 | $57.86 | 7,054 | $408K | 8.1% |
| 10 | $57.86 | 4,600 | $266K | 5.3% |
| 11 | $57.86 | 7,054 | $408K | 8.1% |
| 12 | $58.78 | 6,905 | $406K | 8.0% |
| 13 | $58.78 | 4,506 | $265K | 5.2% |
| 14 | $58.78 | 4,506 | $265K | 5.2% |
| 15 | $58.78 | 6,905 | $406K | 8.0% |
| 16 | $59.48 | 616 | $37K | 0.7% |
| 17 | $59.48 | 942 | $56K | 1.1% |
| 18 | $59.48 | 942 | $56K | 1.1% |
| 19 | $53.73 | 780 | $42K | 0.8% |
| 20 | $53.73 | 1,196 | $64K | 1.3% |
| 21 | $53.73 | 1,196 | $64K | 1.3% |
| 22 | $54.35 | 339 | $18K | 0.4% |
| 23 | $54.35 | 520 | $28K | 0.6% |
| Total | $57.28 avg | 88,447 | $5.1M | 100% |
| Filing → |
| KROS | SELL | 2022-01-05 | $5.3M | — | Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |